Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Ficus septica* exudate is the latex or sap obtained from the *Ficus septica* plant (commonly known as Hauli or Septic Fig), a member of the Moraceae family native to Southeast Asia and Australia. In traditional medicine, it has been utilized for the treatment of skin diseases, wounds, and inflammatory conditions. The exudate is characterized by its high concentration of bioactive phenanthroindolizidine alkaloids, such as tylophorine, ficuseptine, and antofine. These compounds have garnered significant interest in oncology research due to their ability to inhibit protein translation and induce apoptosis in various cancer cell lines. Additionally, the exudate exhibits anti-inflammatory effects by suppressing the NF-kappaB signaling pathway and downregulating pro-inflammatory mediators such as COX-2 and various cytokines. While it is not currently an approved pharmaceutical, it remains a subject of preclinical investigation for its antineoplastic and antimicrobial potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ficus septica exudate.